Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia (2019)
Fonte: Atherosclerosis. Unidade: FM
Assuntos: HIPERCOLESTEROLEMIA, OLIGONUCLEOTÍDEOS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REESKAMP, Laurens F et al. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, v. 280, p. 109-117, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.atherosclerosis.2018.11.017. Acesso em: 21 ago. 2024.APA
Reeskamp, L. F., Kastelein, J. J. P., Moriarty, P. M., Duell, P. B., Catapano, A. L., Santos Filho, R. D. dos, & Ballantyne, C. M. (2019). Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 280, 109-117. doi:10.1016/j.atherosclerosis.2018.11.017NLM
Reeskamp LF, Kastelein JJP, Moriarty PM, Duell PB, Catapano AL, Santos Filho RD dos, Ballantyne CM. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia [Internet]. Atherosclerosis. 2019 ; 280 109-117.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2018.11.017Vancouver
Reeskamp LF, Kastelein JJP, Moriarty PM, Duell PB, Catapano AL, Santos Filho RD dos, Ballantyne CM. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia [Internet]. Atherosclerosis. 2019 ; 280 109-117.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2018.11.017
